Arterial stiffness reduction on GLP-1 — need advice

julia.endo said:

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

This is my experience too, for whatever a second data point is worth.

Dr.PathRoch said:

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated…

That reframing is the part I needed.

Clinical perspective, offered as context rather than as advice.

I want to bring up the cardiovascular angle on cardiovascular risk.

The SELECT trial demonstrated a 20% reduction in MACE with semaglutide 2.4mg[1]. This is practice-changing because the CV benefit appears to be independent of the degree of weight loss — suggesting direct vascular and anti-inflammatory mechanisms.

For cardiovascular risk, this means we need to think beyond the primary outcome and consider the cardiovascular implications. The all-cause mortality reduction (HR 0.81) is the most clinically meaningful signal.

LipidDoc_ATL said:

I want to bring up the cardiovascular angle on cardiovascular risk.

Adding a me-too, because a thread of one person's experience is not much use. Nothing to add that would improve it.

Moderator note: the sourcing question belongs in the vendor section and has been split out.